Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients’ lives by providing innovative and targeted treatment options.
Revenue Compound Annual Growth Rate in the last 5 years.
Operating Income Compound Annual Growth Rate in the last 5 years.
Net Income Compound Annual Growth Rate in the last 5 years.
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
...and much more!